With the exception of the insulin sensitizing peptide adiponectin, adipokine production and secretion are increased in central obesity [10, 11, 15]: this fact plays a pivotal role both in the pathogenesis of cardiovascular damage through adverse effects on hemostatic balance and vascular function [5, 6, 11], and in the amplification of inflammatory processes in vascular and nonvascular tissues [11, 13, 15]. Here, ADIPOQ is linked to Abdominal obesity.